9
Participants
Start Date
November 16, 2016
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
ALLO-ASC-CD
ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
RECRUITING
Seoul National University Hospital, Seoul
COMPLETED
Severance Hospital, Seoul
Anterogen Co., Ltd.
INDUSTRY